XTLB · Xtl Biopharmaceuticals Ltd
$2.96
+0.08 (+2.78%)
At close · Jul 28
Market Cap
$7.27M
Shares
2.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.96
Open$2.83
Day$2.76–2.98
52W$2.01–10.28
Avg vol 30d138K
Short int36K · 1.5% float · 1.0d
Short vol1%
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
+14%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
−12%
trailing
YTD return
+28%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.47% of float · ▲ +286.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
6 holders — near 3-yr high, broad support
Squeeze score
50
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
133%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
+14%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.47% of float · ▲ +286.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
6 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $3 · 11%
52-wk high $10
vs 200-day avg -7%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XTLB
this stock
Xtl Biopharmaceuticals Ltd
|
$7.27M | +27.6% | — | — | 1.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XTLB | +2.4% | +25.4% | -11.9% | +8.4% | +27.6% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +3.4% | +25.4% | -19.3% | +9.2% | +19.0% |